Following an abbreviated submission
Ezetimibe/simvastatin (InegyP®P) is accepted for restricted use in NHS Scotland only for patients who have failed to achieve target cholesterol levels after titration and optimisation of statin monotherapy and where the combination of ezetimibe 10mg and simvastatin 20mg, 40mg or 80mg is appropriate.
This reflects advice on ezetimibe issued by the Scottish Medicines Consortium in September 2003 (61/03) and is based on the combined tablets being priced at approximately the same level as the individual ingredients.
Download detailed advice33KB (PDF)
- Medicine name:
- ezetimibe/simvastatin (Inegy)
- SMC ID:
- Hypercholesterolaemia and Homozygous Familial Hypercholesterolaemia
- Pharmaceutical company
- MSD/Schering Plough
- BNF chapter
- Cardiovascular system
- Submission type
- Date advice published
- 13 June 2005